Cash position of €62 million at year-end provides runway until the end of H2 2022 Enrolment of SENS-401 Phase 2 SSNHL clinical study progressing Expanding
Cash position of €62 million at year-end provides runway until the end of H2 2022 Enrolment of SENS-401 Phase 2 SSNHL clinical study progressing Expanding